Current advances in immunotherapy for cancer
Recent advances in cancer immunotherapy, including immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T-cell therapy, have significantly improved the clinical management of various cancers. ICIs, such as PD-1/PD-L1 and CTLA-4 inhibitors, enhance the body's immune response a...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Oral Oncology Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772906024004989 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846139837582671872 |
|---|---|
| author | Indrajit Desai Saee Thakur Pradeep Pagariya |
| author_facet | Indrajit Desai Saee Thakur Pradeep Pagariya |
| author_sort | Indrajit Desai |
| collection | DOAJ |
| description | Recent advances in cancer immunotherapy, including immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T-cell therapy, have significantly improved the clinical management of various cancers. ICIs, such as PD-1/PD-L1 and CTLA-4 inhibitors, enhance the body's immune response against tumors, offering substantial benefits in cancers like melanoma, non-small-cell lung cancer, and lymphoma. CAR-T cell therapy has demonstrated remarkable efficacy in hematologic malignancies, particularly B-cell leukemias and lymphomas, through the genetic modification of T-cells to target tumor-specific antigens.Despite these successes, several challenges remain, particularly in the treatment of solid tumors. The heterogeneity of tumor antigens, the presence of physical barriers that impede CAR-T cell infiltration, and the immunosuppressive tumor microenvironment limit the effectiveness of these therapies. To address these issues, ongoing research is exploring combination therapies that integrate ICIs with CAR-T cell therapy, improved CAR-T cell engineering, and strategies to modulate the tumor microenvironment to enhance immune cell infiltration and function. |
| format | Article |
| id | doaj-art-4bc04bb9fb1a4f209dbf47acb5d8086b |
| institution | Kabale University |
| issn | 2772-9060 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Oral Oncology Reports |
| spelling | doaj-art-4bc04bb9fb1a4f209dbf47acb5d8086b2024-12-06T05:15:17ZengElsevierOral Oncology Reports2772-90602024-12-0112100652Current advances in immunotherapy for cancerIndrajit Desai0Saee Thakur1Pradeep Pagariya2KIT College of Engineering, Kolhapur, India; Corresponding author.KIT College of Engineering, Kolhapur, IndiaM.J. Biopharma Pvt. Ltd., Pune, IndiaRecent advances in cancer immunotherapy, including immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T-cell therapy, have significantly improved the clinical management of various cancers. ICIs, such as PD-1/PD-L1 and CTLA-4 inhibitors, enhance the body's immune response against tumors, offering substantial benefits in cancers like melanoma, non-small-cell lung cancer, and lymphoma. CAR-T cell therapy has demonstrated remarkable efficacy in hematologic malignancies, particularly B-cell leukemias and lymphomas, through the genetic modification of T-cells to target tumor-specific antigens.Despite these successes, several challenges remain, particularly in the treatment of solid tumors. The heterogeneity of tumor antigens, the presence of physical barriers that impede CAR-T cell infiltration, and the immunosuppressive tumor microenvironment limit the effectiveness of these therapies. To address these issues, ongoing research is exploring combination therapies that integrate ICIs with CAR-T cell therapy, improved CAR-T cell engineering, and strategies to modulate the tumor microenvironment to enhance immune cell infiltration and function.http://www.sciencedirect.com/science/article/pii/S2772906024004989Checkpoint inhibitorPD-1 inhibitorPDL-1 inhibitorCTLA-4 inhibitorCAR-T cell therapy |
| spellingShingle | Indrajit Desai Saee Thakur Pradeep Pagariya Current advances in immunotherapy for cancer Oral Oncology Reports Checkpoint inhibitor PD-1 inhibitor PDL-1 inhibitor CTLA-4 inhibitor CAR-T cell therapy |
| title | Current advances in immunotherapy for cancer |
| title_full | Current advances in immunotherapy for cancer |
| title_fullStr | Current advances in immunotherapy for cancer |
| title_full_unstemmed | Current advances in immunotherapy for cancer |
| title_short | Current advances in immunotherapy for cancer |
| title_sort | current advances in immunotherapy for cancer |
| topic | Checkpoint inhibitor PD-1 inhibitor PDL-1 inhibitor CTLA-4 inhibitor CAR-T cell therapy |
| url | http://www.sciencedirect.com/science/article/pii/S2772906024004989 |
| work_keys_str_mv | AT indrajitdesai currentadvancesinimmunotherapyforcancer AT saeethakur currentadvancesinimmunotherapyforcancer AT pradeeppagariya currentadvancesinimmunotherapyforcancer |